Eli Lilly的新减重药导致肥胖成人体重下降9.5 20.1%, Eli Lilly's new weight loss drug caused 9.5%–20.1% weight loss in obese adults, outperforming placebo and improving health markers.

根据《柳叶刀》第2阶段的试验结果,在不患2型糖尿病的超重或肥胖成年人中,Elilily的实验性减重药物埃利诺丁(Amylin 类比)导致体重减少9.5%至20.1%,而在安慰剂组中,这一比例为0.4%。 Eli Lilly's experimental weight loss drug eloralintide, an amylin analog, led to 9.5% to 20.1% body weight loss in overweight or obese adults without type 2 diabetes, compared to 0.4% in the placebo group, according to Phase 2 trial results published in The Lancet. 仿制荷尔蒙阿米林以调节食欲和消化, 也改善了血压、胆固醇及炎症标记。 The once-weekly drug, which mimics the hormone amylin to regulate appetite and digestion, also improved blood pressure, cholesterol, and inflammation markers. 早期数据表明,比起GLP-1型药物,它可能保持更瘦的肌肉质量。 Early data suggest it may preserve more lean muscle mass than GLP-1 drugs. Elilly计划在今年晚些时候开始第3阶段的试验,Novo Nordisk等其他公司也推进类似的治疗。 Eli Lilly plans to begin Phase 3 trials later this year, with other companies like Novo Nordisk also advancing similar treatments.